Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2738 - Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)


08 Oct 2016


Poster Display


Fabrice Barlesi


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


F. Barlesi1, A.C. Dingemans2, J.C. Yang3, S.I. Ou4, J.S. Ahn5, L. De Petris6, B. Hughes7, H. Lena8, W. Bordogna9, S. Golding10, P.N. Morcos11, B. Balas12, A. Zeaiter9, D. Kim13

Author affiliations

  • 1 Multidisciplinary Oncology & Therapeutic Innovations, Aix Marseille University; Assistance Publique Hôpitaux de Marseille, 13915 - Marseille/FR
  • 2 Pulmonology, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL
  • 3 Graduate Institute Of Oncology, National Taiwan University, Taipei/TW
  • 4 Chao Family Comprehensive Cancer Centre, University of California Irvine School of Medicine, Orange/US
  • 5 Department Of Hematology & Oncology, Samsung Medical Center, Seoul/KR
  • 6 Oncology, Karolinska University Hospital, Stockholm/SE
  • 7 Cancer Care Services, The Prince Charles Hospital Queensland Australia, Brisbane/AU
  • 8 Pneumologie, Centre Hospitalier Universitaire, Rennes/FR
  • 9 Product Development, F. Hoffmann-La Roche Ltd, Basel/CH
  • 10 Pd Biostatistics, F. Hoffmann-La Roche Ltd, Basel/CH
  • 11 Clinical Pharmacology, F. Hoffmann-La Roche Ltd, New York/US
  • 12 Safety Risk Management, F. Hoffmann-La Roche Ltd, Basel/CH
  • 13 Department Of Internal Medicine, Seoul National University Hospital, Seoul/KR


Abstract 2738


Alectinib is an FDA-approved ALK inhibitor for pts with ALK+ NSCLC, who have progressed on, or are intolerant to, crizotinib. Alectinib has shown systemic and CNS activity in previously treated pts in two pivotal phase II trials (NCT01801111 [NP28673] and NCT01871805 [NP28761]). We report updated safety and efficacy (data cut-off 01 Feb 2016) from the global NP28673 study (previously at ECC 2015 [Barlesi et al]).


Pts ≥18 yrs, ECOG PS 0–2 with confirmed ALK+ NSCLC (by FDA-approved FISH) previously treated with crizotinib received alectinib 600mg BID until progression, death or withdrawal. Co-primary endpoints were objective response rate (ORR) by Independent Review Committee (IRC) in the response evaluable (RE) population using RECIST v1.1 and in pts who had prior chemo. Secondary endpoints included duration of response (DOR); CNS ORR and DOR; disease control rate (DCR); PFS; OS; and safety (CTC v4.0).


138 pts were enrolled (ITT), median age 52 yrs; 110 had received prior chemo, 84 had baseline (BL) CNS mets. At this data cut-off, median follow-up was 21 months. The co-primary endpoint IRC ORR (n = 122) was 50.8% (95% CI 41.6–60.0); DCR: 78.7% (95% CI 70.4–85.6); median DOR: 15.2 months (95% CI 11.2–24.9); and median PFS: 8.9 months (95% CI 5.6–12.8). In pts with prior chemo (n = 96), IRC ORR was 44.8% (95% CI 34.6–55.3); DCR: 77.1% (95% CI 67.4–85.1) and median DOR: 14.7 months (95% CI 10.2–21.9). See table for data in pts with CNS mets at BL. Median OS in ITT pts was 26.0 months (95% CI 21.5–NE) after 44% events. Most common AEs (any grade): constipation (38%); fatigue (31%); peripheral oedema (30%). Rates of AEs leading to dose modification/interruption (28%) or withdrawal (9%) show good tolerability.

Measurable CNS mets (n = 34) Measurable and non-measurable CNS mets (n = 84)
IRC CNS ORR, % (95% CI) 58.8 (40.7–75.4) 46.4 (35.5–57.7)
CNS DCR, % (95% CI) 85.3 (68.9–95.1) 84.5 (78.0–91.5)
Complete response, n (%) 7 (21) 26 (31)
Partial response, n (%) 13 (38) 13 (16)
Stable disease, n (%) 9 (27) 32 (38)
Median CNS DOR, mos (95% CI) 11.1 (7.1–NE) 11.2 (9.1–NE)


The updated NP28673 data show that alectinib is well tolerated and efficacy is robust, both systemically and in the CNS. The ongoing phase III ALEX trial is evaluating alectinib vs crizotinib in a first-line setting.

Clinical trial identification

NCT01801111 [NP28673] and NCT01871805 [NP28761].

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd


F. Hoffmann-La Roche Ltd


F. Barlesi: Advisory board and Corporate-sponsored research for F. Hoffman-La Roche. A-M.C. Dingemans: Roche Advisory board or board of directors. J.C-H. Yang: Membership on an Advisory Board for BI, Eli Lilly, Bayer, Roche/Genentech/Chugai, Astrazeneca, Astellas, MSD, Merck Serono, Pfizer, Novartis, Clovis Oncology, Celgene, innopharma, Merrimack. S-H.I. Ou: Roche Advisory Board, Corporate Sponsored Research and Speakers Bureau. B. Hughes: Roche Advisory Board. H. Lena: Roche Corporate-sponsored research. W. Bordogna: Employment with Hoffmann-La Roche. S. Golding, B. Balas: Employee and Stock ownership for F. Hoffmann-La Roche. A. Zeaiter: Employee, Leadership and Stock Ownership for F. Hoffmann-La Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings